Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

You are here: Industry Insights > Market News > Alkem’s St Louis facility gets two observations from US FDA

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

TAYACN Drying Ammonium thiocyanate ZLG series vibration fluidized bed dryer

TAYACN Drying Ammonium thiocyanate ZLG series vibration fluidized bed dryer

TAYACN Drying Nickel chloride water ZLG series vibration fluidized bed dryer

TAYACN Drying Nickel chloride water ZLG series vibration fluidized bed dryer

TAYACN Drying Flavoring ZLG series vibration fluidized bed dryer

TAYACN Drying Flavoring ZLG series vibration fluidized bed dryer

TAYACN Drying Resin ZLG series vibration fluidized bed dryer

TAYACN Drying Resin ZLG series vibration fluidized bed dryer

TAYACN Drying Thiourea particles ZLG series vibration fluidized bed dryer

TAYACN Drying Thiourea particles ZLG series vibration fluidized bed dryer

TAYACN Drying Sodium percarbonate ZLG series vibration fluidized bed dryer

TAYACN Drying Sodium percarbonate ZLG series vibration fluidized bed dryer

Alkem’s St Louis facility gets two observations from US FDA

expresspharmaJune 21, 2021

Tag: FDA , Alkem , facility

Favorites

Alkem Laboratories informed that the US FDA has issued Form 483 with two observations for its manufacturing facility located in St Louis, US. The US FDA had conducted an inspection of the company’s manufacturing facility from 14-18, June 2021.

The company also informed that it will submit to US FDA within the stipulated timeline, a detailed response to close out all the observations associated with this inspection.

Previous:Study shows corticosteroids may be effective in treating COVID-19 complications in children

Next:Israeli scientists find promising target for breast cancer and other cancer therapeutics

Related News

Alzheimer’s Disease: Charting the Course from Plaques to Promise

Muhammad Farhan KhalidMay 28, 2025

New Tools，New Hope，New Frontier

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

Alkem’s St Louis facility gets two observations from US FDA | Pharmasources.com

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Telix Pharmaceuticals Limited announces that the pivotal Phase 3 registration study of TLX591-CDx for prostate cancer imaging in Chinese patients has completed patient enrolment.

You may like
More>>

Rutin(FDA:26509)

Rutin(FDA:26509)

Vecuronium (FDA)

Vecuronium (FDA)

Semaglutide(FDA)

Semaglutide(FDA)

Cilostazol(FDA Approved) (Micronized)

Cilostazol(FDA Approved) (Micronized)

Hemisuccinate /Sodium (FDA/DMF)

Hemisuccinate /Sodium (FDA/DMF)

Tobramycin base( FDA)

Tobramycin base( FDA)

Sunitinib(FDA:26464)

Sunitinib(FDA:26464)

Dasatinib(FDA:26494)

Dasatinib(FDA:26494)

Letrozole(FDA:26252)

Letrozole(FDA:26252)

9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)

9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

About Us: About PharmaSources; Terms of Service; Privacy Policy; Event Data Sharing Notice; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Copyright 2006-2025 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 滬ICP備05034851號(hào)-182 滬公網(wǎng)安備31010402010101號(hào)
Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight January 2025

PharmaSources Customer Service